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ABSTRACT 
 
IMPORTANCE: Age-related macular degeneration (AMD) is a leading cause of low 
vision in elderly population. The association of vascular and renal conditions has been 
reported inconsistently. Unfolding the association may provide the insight to eye care 
providers to take account general health management into eye care.   
OBJECTIVES:  To investigate the prevalence of the vascular and renal comorbidities 
with AMD, examine the association of a single or combination of these comorbidities 
with AMD.  
DSIGN AND PARTICIPANTS: Population-base cross-sectional study involved the 
adults aged 40 years or older (N=4596) who participated in the 2005 to 2008 National 
Health and Nutrition Examination Survey (NHANES), a national representative 
population-based survey of non-institutionalized US residents.  
MAIN OUTCOMES AND MEASURES: AMD was defined by the presence of drusen 
and presence of pigmental abnormality. Angina pectoris (AP), coronary heart disease 
(CHD), congestive heart failure (CHF) and myocardial infarction (MI), and stroke, 
assessed by self-report by the questionnaire of medical conditions, Chronic kidney 
disease (CKD), assessed by self-report and estimation of glomerular filtration rate (GFR) 
and the level of urine albumin. Heart disease (HD) was defined as having AP or CHF or 
CHD or MI.  
RESULTS:  Among individuals with AMD, 6% had AP, 10% had CHD, 7% had CHF, 
10% had MI, 13% had stroke, and 29% had CKD. The weighted prevalence of these 
conditions were significantly higher than those without AMD (All P-values <0.05). The 
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estimated crude odds ratios (ORs) for the association between a single comorbidity and 
AMD were the following: 1.96 (95%CI: 1.24-3.10) for AP; 2.46 (95%CI, 1.67-3.64) for 
CHD, 2.38 (95% CI, 1.64-3.45) for  MI, 2.51 (95% CI, 1.60-3.95) CHF, 2.59 (95% CI, 
1.95-3.43) HD, 3.91( 95%CI, 2.72-4.36) for stroke, and 3.35 (95% CI, 2.57-4.36) for 
CKD. Adjusting for gender, age and other risk factors, ORs were attenuated but 
remained elevated and statistically significant; whereas, AP was no long significantly 
associated with AMD. One of three comorbidities (HD, Stroke and CKD) ( Crude OR: 
2.78 (95%CI: 2.00-3.78); adjusted OR: 2.60 (95% CI: 1.71-3.92)), combination of the 
comorbidities (Crude OR: 3.93 (95%CI: 2.69-5.73); adjusted OR: 2.33 (95%CI: 2.73-
3.99)) were associated with AMD. The association of the combination of CKD and 
Stroke was the strongest (Crude OR: 7.43 (95%CI: 4.51-12.27); adjusted OR: 5.50 
(95% CI: 2.74-12.02)). 
CONCLUSION AND RELEVANCE: These findings from the nationally-representative 
sample of the US population highlight the prevalence of vascular and renal 
comorbidities associated with AMD, the modest evidence of relationship of each single 
comorbidity, and strong association of combination of stroke and CKD to AMD 
independent of age, gender, and other factors. Because of the cross-sectional design, 
the results of this study can not address a causal relationship between AMD and the 
examined comorbidities. It is unclear whether AMD and comorbidities arise from 
individual predisposition to vascular and renal diseases or whether complications from 
these morbidities increase the risk of AMD. However, the important caveat is that 
preventive and care management for the examined comorbidities may lessen the 
severity of symptoms or prevent AMD.  
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CHAPTER I  
INSTRUCTION 
 Age-related macular degeneration (AMD) is one of most common ocular 
diseases in the elderly population. The prevalence of AMD is reported as 9.8% among 
people aged 65 years or older, while 6.5% in individuals aged 40 years or older in US 
population (Klein et al., 2011; Klein et al., 2010). Although the prevalence of AMD 
decreases from 9.4% to 6.5% in US population aged 40 years or older during the last 
decade (Klein, et al., 2011; Klein et al., 1999), it is still a contributable cause of visual 
impairment and blindness (Chou et al., 2013; Foran, Wang, & Mitchell, 2003), which 
significantly impact on individual health quality of life, and increase severity of public 
health concern. Gaining population-based evidence of AMD is significant for lowing the 
incidence of AMD and blindness since the effective treatment and clinical management 
of AMD remains challenge (van Lookeren Campagne, LeCouter, Yaspan, & Ye, 2014).  
 
 Concurrence of medical conditions is more prevalent with age, one of four 
Americans has two or more conditions age more than 40 years. AMD, a multifactoral 
disease, is more likely coexisting with the diseases which share common risk factors or 
biological plausible pathways. The substantial presence of the associated comorbidities 
of AMD could resulted in an increased frequency of disability of vision impairment and 
overall burden of diseases to our society. Study on the association between these 
comorbidities and AMD would predict the outcomes of AMD and provide the insight for 
eye care management so as to reduce the worse outcome.  
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 Heart diseases, stroke and chronic kidney disease (CKD ) are major vascular 
diseases, and each of them shares common risk factors of AMD. The linkage between 
these conditions and AMD has been reported, but the results were inconsistent. A study 
has reported that AMD may be the risk predictor of coronary heart disease (CHD) 
relating to high mortality (Tan, Wang, Liew, Rochtchina, & Mitchell, 2008), by contrast, 
another study has showed that AMD is not associated with CVD and CHD (Fernandez 
et al., 2012). The AMD was associated with stroke (Tan, et al., 2008), but not 
associated with cerebral infarction (Wieberdink et al., 2011), moreover, the early AMD is 
not a risk factor of stroke in people aged 69 to 97 years (Sun, Klein, & Wong, 2009). 
CKD patients are in a higher risk of early AMD (Liew, Mitchell, Wong, Iyengar, & Wang, 
2008). With the inconsistency, there is a rationale for an investigation of the relationship 
between vascular and renal comorbidities and AMD because the substantial present of 
these associated comorbidities would increase overall health burden of AMD in both 
individual and society level. The measurement of concurrence between AMD and the 
comorbidities will unfold the association by using national representative population, it 
will lead to the better visual outcomes of AMD patients, if these comorbidities are taken 
account into eye care management. 
 We conducted a study to investigate whether there is an association between 
AMD and vascular and renal conditions including heart disease (HD) containing angina 
pectoris (AP), coronary heart disease (CHD), congestive heart failure (CHF) and 
myocardial infarction (MI), stroke and chronic kidney disease (CKD). We utilized the 
data of 2005 - 2008 National Health and Nutrition Examination Survey (NHANES), a 
national representative sample of US population. We compared the prevalence of these 
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vascular and renal diseases among individual with AMD to those without AMD. We 
analyzed the association between AMD and each vascular and renal medical condition. 
We explored the relationship between AMD and combination of  three conditions (HD, 
Stroke and CKD). We hypothesized that the individuals with these vascular and renal 
medical conditions will have an association with AMD, the association with combined 
comorbidities may be stronger comparing to the single comorbidity.   
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CHAPTER II 
REVIEW OF LITERATURE 
II.I Age-related Macular Degeneration 
 Age-related macular degeneration (AMD) is a neurodegenerative ocular disease 
affecting the population aged 40 years or older. It is a leading cause of blindness 
accounting for up to 50% of all cases of legal blindness in the United States. The typical 
lesion of AMD occurs at the retinal macular area. The damage to the macula results in 
impairment of central acuity and eventually loss of vision. AMD is categorized in two 
stages based on clinical manifestations: early and late AMD. The early AMD is 
asymptomatic with the appearance of numerous large drusen in the retina identified by 
retinal image. The drusen develop from the slow progressive degeneration of the retinal 
pigment epithelium and retinal photoreceptors (Lengyel et al., 2004). Early AMD 
accounts for approximately 80% of the reported cases of all AMD. Late AMD is divided 
into two types: choroidal neovascularization (CNV, also known as wet AMD) and 
geographic atrophy (GA, also known as dry AMD) based on presence or absence of 
invasive new blood vessels in the retina (Zweifel, Imamura, Spaide, Fujiwara, & Spaide, 
2010). Late AMD accounts for about 20% of all AMD; however, late AMD is responsible 
for majority of blindness (Bourne et al., 2013). Several novel treatments for late AMD 
have been identified. An intraocular injection of an anti-vascular endothelial growth 
factor (VEGF) agent (Akpek & Smith, 2013) is available for treatment of the CNV type of 
AMD. These agents have substantially gained the vision back and reduced the risk of 
blindness in some but not all patients. In contrast, there is no approved treatments for 
GA type of AMD. Effective management of AMD remains a significant challenge. Early 
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detection and prevention of AMD, therefore, is important to reduce the incidence of 
AMD and improve the quality of vision. Population-based epidemiological studies are 
capable of providing the evidence for the etiology of AMD in order to establish of 
prevention program of reduction of risk factors of AMD. 
 
II.II Pathogenesis of AMD 
 AMD is generally considered as a complex genetic disorder influenced by 
environmental risk factors. Although biological mechanisms of AMD are largely 
unknown, major progress in understanding the pathogenesis of AMD have been made 
through the advances of molecular cell biology and genetics in the past decade 
implicating several pathogenetic pathways including oxidative damage, chronic 
inflammation, and excessive accumulation of lipofuscin, (Whitcup et al., 2013).  
Activation of immune cells in the retina, including microglia cells, Muller cells RPE cells 
and macrophages related to the pathway of GA type of AMD (Cherepanoff, 
McMenamin, Gillies, Kettle, & Sarks, 2010). Complement activation is reported to 
associated to the inflammation pathophysiological way of AMD. Molecular pathological 
evidence of oxidative damage in the retina linked to immune response has indicated the 
relevance of oxidative stress to initiate the development of AMD (Hollyfield et al., 2008).  
In addition, it is very accepted that genetic contribution is strongly correlated to the risk 
of AMD. Genetic analyses reveal that there is correlation between GA type of AMD risk 
and variations in genes encoding negative regulators in complement pathways, 
including complement factor H (CFH) and factor I (CFI ), as well as additional 
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components of the AP such as complement factors B (CFB) and C3 (Fagerness et al., 
2009; Heurich et al., 2011).  
 
II.III The Epidemiology of AMD 
 The population of AMD patients bears the greatest burden of health due to 
disabilities in vision loss, complications and co-morbidities. Population-based studies on 
AMD are vital for understanding the etiology of AMD to reduce the burden of disease. 
There have been many epidemiological studies on the prevalence and incidence of 
AMD and decreased trend of prevalence of AMD is observed. The Framingham Eye 
Study reported the prevalence of AMD among people aged 52-85 years was 8.8% 
(Leibowitz et al., 1980). A fifteen year accumulative prevalence of ADM study has 
shown the prevalence of early stage of AMD was 24%, late state was 8% among people 
aged 75 and older (Klein et al., 2007). The Beaver Dam Offspring study estimated a 
9.8% prevalence of AMD among people aged more than 65 years (Klein, et al., 2010).  
In the US population aged 40 years and older, the prevalence of any AMD was 6.5% 
and the prevalence of late AMD was 0.8% (Klein, et al., 2011). The disparity of 
prevalence of AMD among racial/ethnic groups has been observed and the prevalence 
of AMD is higher among the whites than any other racial groups. Dr. Klein et al's study 
has shown that blacks aged 60 years and older had a lower prevalence of AMD (OR = 
0.37; 95% CI, 0.21-0.67) than non-Hispanic white persons in the same age groups 
(Klein, et al., 2011).  It is thought that the prevalence of AMD does not differ from 
gender, although women have higher risk of CNVAMD (OR:1.2; 95% CI: 1.0-1.5 ) in one 
study (Owen et al., 2012). The population-based studies have led to major advances in 
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the understanding of the risk factors of AMD.  A meta-analysis has reported that 73 risk 
factors of AMD are associated with AMD, and aging, cigarette smoking, previous 
cataract surgery and a family history of AMD are the risk factors consistently 
(Chakravarthy et al., 2010).  In addition, factors of social economic status, oxidative 
stress (Hollyfield, et al., 2008), low level of antioxidants (Chew et al., 2013) and 
nutritional factors (Chew, et al., 2013; Wlodarek & Glabska, 2011) have been implicated 
as risk factors for the occurrence of AMD.  Many of the etiological risk factors of AMD 
are commonly shared with medical conditions of different organ systems.  Exploring the 
relationship between ADM and organ system diseases is ideal for understanding the 
etiology of AMD. 
 
 II.IV Vascular and Renal Comorbidities and AMD  
 Comorbidity is widely defined as the presence of more than 2 diseases in an 
individual. These conditions could be occurring synchronously or sequentially. For 
example, a patient with established depression is diagnosed with a glaucoma differs 
from a patient with depression and later is found to have a glaucoma. Comorbidity is 
usually associated with a worse outcome, consequently increasing health care cost. 
About 80% of health care expenditure in the United States is spent on patients who 
have 4 or more chronic diseases (Wolff, Starfield, & Anderson, 2002). Comorbidities 
often display either common etiological pathways or biological plausibility, hence the 
information of comorbidity predicts not only the disease pathogenesis, prognosis, and 
treatment, but also the burden of organ dysfunction. From the point view of 
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epidemiology and public health, understanding the comorbidity is very important as 
comorbidity is associated with a worse outcome.  
 Heart disease (HDs) share many common risk factors with AMD suggesting that 
HDs may be a comorbidity of AMD.  CVDs generates the most health concerns 
because of high incidence and prevalence. The estimation from 2007-2010 NHANES 
(National Health and Nutrition Examination Survey ), is that one of third deaths was 
attributable to CVDs in United States in 2009. One of six deaths is caused by CHD; one 
of nine deaths is from congestive heart failure; one of every nineteen deaths is 
attributable to stroke; one third of US adults aged 20 years and older have hypertension 
(Go et al., 2013). In s population based cohort study in middle-aged persons, 
participants with any AMD were at an increased risk of stroke with a stronger 
association for intracerebral hemorrhage than cerebral infarction after a mean follow-up 
13 years (Ikram et al., 2012).  Total serum cholesterol was associated directly with 
incident geographic atrophy (Tomany et al., 2004). AMD often coexists with CVD due to 
a shared pathogenesis. In this thesis study, common cardiovascular diseases listed in 
NHANES dataset are chosen to investigate the epidemiological linkage with AMD .     
 The association between Coronary heart disease (CHD) and AMD has long been 
postulated by epidemiological studies, but the results of the association vary. Several 
epidemiological studies have suggested the association between CHD and AMD. The 
linkage between the early AMD and an increased risk of  CHD (HR1.57; 95% CI, 1.17-
2.22) is described in the Cardiovascular Health Study  in the Australian population aged 
69-97 (Sun, et al., 2009), Another prospective cohort study has suggested an 
association between early AMD and CHD (RR: 1.08; 95% CI 0.82-1.42) in a middle 
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aged Australian population, but the individuals with late AMD had three times higher risk 
of incident CHD events (HR= 3.05, 95% CI, 1.14–8.17) (Wong et al., 2007). A case 
control study investigating a French population suggested a link between AMD and 
CHD (RR: 1.31, 95%CI: 1.02–1.68) (Chaine et al., 1998). Blue Mountains Eye Study 
has stated that early AMD had a 2-time increased risk of CHD mortality controls (HR= 
2.32, 95% CI, 1.03 to 5.19) (Tan, et al., 2008). On the other hand, the most recent study 
has stated that AMD is a not risk indicator of CHD in the Multi-Ethics Study of 
Atherosclerosis (HR: 0.99; 95% CI, 0.74-1.33) in the population aged 45 to 84 years 
with an over 5.4 year follow-up (Fernandez, et al., 2012). The results implied the 
importance for further study of the association between CHD and AMD with a national 
representative population.  
 Heart attack (HA), also known as Myocardial infarction (MI), is one of the most 
common cardiovascular diseases and is a consequent of ischemic heart disease 
accounting for 12.2% of worldwide deaths based on the estimate of WHO in 2004. 
Many risk factors of MI have been postulated in epidemiological studies including age, 
smoking, abnormality of blood levels of certain lipids, diabetes, hypertension, and 
obesity. Previous cardiovascular disease is the most common risk factor of MI. Angina 
Pectoris commonly is thought to be related to myocardial ischemia. Angina also shares 
most of the same risk factors with MI. Heart failure also known as congestive heart 
failure (CHF) commonly results from cardiovascular diseases including MI. Heart failure 
affected 5.8 million people in the United States in 2011. The health care expenditure for 
heart failure exceeds $35 billion in the United States due to the hospitalization cost 
(Rosamond et al., 2008). The risk factors of CHF includes ischaemic heart disease, 
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hypertension, obesity, and diabetes which are major risk factors for MI and angina 
pectoris. Given these same risk factors of angina, MI and CHF with AMD, it is 
considerable that there is an association between AMD and angina, MI and CHF. 
However, there is no common agreement that this association exists. When reviewing 
the evidence from epidemiological studies. There is no association between angina, MI 
and AMD in Beaver Dam Eye Study (Klein et al., 2013). MI or angina RR was related 
with AMD (HR:1.57; 95% CI: 1.13-2.16) (Tan, et al., 2008), persons with MI was 
significantly more prevalent for early AMD (Liutkeviciene et al., 2012), furthermore, MI 
was associated with AMD, particularly in neovascular AMD (HR: 1.19; 95%CI: 1.16-1.22) 
(Duan et al., 2007). To the contrary, a study using a group of hospitalized 
cardiovascular disease patients  reported that the rate ratio for MI with neovascular 
AMD was protective (HR: 0.58; 95% CI: 0.48-0.72) (Nguyen-Khoa et al., 2008) (Golan 
et al., 2011). It is important to investigate the epidemiological relationship between AMD 
and angina, MI and CHF with a national population.  
 Stroke was defined as a "neurological deficit of cerebrovascular cause that 
persists beyond 24 hours or is interrupted by death within 24 hours” World Health 
Organization, 1978  WHO’s top ten causes of death list stroke as the second most 
cause of death worldwide in 2011, accounting for 6.2 million deaths. Risk factors for 
stroke that were identified include age, hypertension, previous stroke or transient 
ischemic attack (TIA), diabetes, and smoking (Donnan, Fisher, Macleod, & Davis, 
2008).  High blood pressure is the most important modifiable risk factor of stroke. As a 
result, stroke may be linked with AMD. There is no general agreement on this linkage 
based on the literature review.  
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 The presence of early-stage AMD in persons aged 49 to 73 was associated with 
a higher adjusted risk for stroke (HR: 1.87 [95% CI, 1.21- 2.88]) over ten years follow up  
(Wong et al., 2006). In a Taiwanese population-based study, neovascular AMD in 
patients aged 65 and older was associated with a 2-fold increased incidence of stroke 
(Hu, Ho, & Lin, 2010). Moreover, AMD was an indicator of the risk of stroke (HR: 1.51; 
95% CI: 1.11-2.06) with an association for  both intracerebral hemorrhage (HR: 2.64; 
95% CI: 1.18-5.87) and cerebral infarction (HR: 1.42; 95% CI: 1.01-1.99) in the 
Atherosclerosis Risk in Communities (ARIC) Study (Ikram, et al., 2012). 
In contrary, a retrospective cohort study using hospitalized CVD database found 
contradictory results and the rate of cerebrovascular accidents (CVAs) was lower in  
neurovascular AMD (RR =0.56, 95% CI, 0.45–0.70) over a 3 year period (Nguyen-Khoa, 
et al., 2008). There is no relationship between AMD and Stroke in the Cardiovascular 
Health Study (Sun, et al., 2009) and the Beaver Dam Eye Study (Klein, et al., 2013). 
Late AMD was associated with an increased risk of any stroke (HR: 1.56; 95% CI: 1.08 -
2.26), and there was a strong association with intracerebral hemorrhage (HR: 6.11; 95% 
CI: 2.34-15.98), but no association with cerebral infarction in the Rotterdam Study 
(Wieberdink, et al., 2011). Future studies on AMD as an indicator of the risk of stroke is 
important.  
 Chronic kidney disease (CKD) shares common pathogenetic mechanisms of 
AMD including inflammation, oxidative stress, and microvascular dysfunction, 
suggesting that CKD may be linked with AMD. A few epidemiological studies of the link 
between AMD and CKD have been reported. CKD was associated with AMD (OR, 1.68; 
95% CI, 1.04-2.72) (Choi, Moon, & Shin, 2011). Proteinuria and eGFR < 45 ml/min/1.73 
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m were positively associated with AMD only among men (OR2.06, 95% CI 1.05, 4.04) 
(Nitsch, Evans, Roderick, Smeeth, & Fletcher, 2009). Mild CKD was associated with the 
15 year cumulative incidence of early AMD (OR: 1.36, 95% CI, 1.00-1.86]) in the Beaver 
Dam Eye Study (Klein, Knudtson, Lee, & Klein, 2009), the 5-yr incidence of early AMD 
with CKD was 4 times higher than those without CKD in the Australian population (Liew, 
et al., 2008), and had a higher prevalence of AMD (1.7% vs. 0.9%, P = 0.01) in a 
Chinese population-based study (Gao et al., 2011). However, little research of CKD and 
AMD with a national population of US has been reported.  
 This thesis study aims to investigate the association between AMD and vascular 
medical conditions including cardiovascular diseases (AP, CHD, MI and CHF), stroke 
and CKD.   
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CHAPER III 
METHODS 
III.I Study Population 
  NHANES is a national representative population-based survey of non-
institutionalized US residents conducted by the National Center for Health Statistics, the 
Centers for Disease Control and Prevention (CDC). The subjects, collection and 
program description have been published at CDC website. NHANES utilized a complex, 
multistage cluster sampling design to achieve the generalizability of US population. In 
brief, subjects contain entire non-civilian population in the United States. Data collection 
was through a questionnaire survey, medical examination and laboratory tests. Retinal 
image photography was conducted 2005 to 2008 and limited to the participants aged 40 
years old and older. Data from NHANES 2005 to 2008 were used for this study. Of the 
total 20,497 subjects, 6,874individuals were more than 40 years old, and 4,596 (66.9%) 
individuals has complete retinal image photography at the time of the completion. 
Among the individuals aged more than 40 years, 49.7% were male and 50.4% were 
female. To the distribution of racial/ethnicity, non-Hispanic white were 39.2%, non-
Hispanic black were 24.0%, Mexican American were 24.4%, and other races/ethnicities 
were 12.3%.  The education distribution shows 54.1% were high school graduate or low, 
26.8% indicated some college, 19.1% were college graduate or above. 
 
III.II Sociodemographic and clinical characteristics   
 Standardized the questionnaires were administered in the home. Physical and 
medical lab examinations were conducted in the NHANES examination center by 
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trained medical professionals. The demographic, social behavioral and clinical 
characteristics were defined for the analysis. Race/Ethnicity was categorized into four 
groups: Non-Hispanic Whites, Non-Hispanic Blacks, Mexican American and other race. 
Education was defined as high school graduate, College or Associate and College 
graduates or more. Family annual incomes were categorized as less than $25,000, 
$25,000 - $49,000, $50,000 - $74,999 and greater than $75,000. Smoking status and 
alcohol consumption were dichotomized as none current smoker and current smoker, 
none regular drinker and regular drinker, respectively. Body Mass Index (BMI) was 
determined as four categories: Less than 18.5, 18.5 to 24.99, 25-29.99 and greater than 
30. Lipid profiles including total cholesterol (TLC), Triglycerides, Low density lipoprotein 
(LDL); High density lipoprotein (LDL) were categorized as the levels based on the 
American Heart Association (AHA) recommends.  For the TCL levels: less than 200 
mg/dL, 200-239 mg/dL, greater that 240 mg/dL; Level of Triglycerides levels: less than 
150 mg/dL, 150-199 mg/dL, 200-500 mg/dL and greater than 500mg/dL. Level of LDL: 
less than 129 mg/dL, 130-159 mg/dL, 160-190 mg/dL and greater than 190 mg/dL. 
Level of HDL: less than 40 mg/dL, 40-60 mg/dL and greater than 60 mg/dL, 
respectively.  
 
III.III Definition of Variables of the Comorbidities  
 The comorbidities of AMD for cardiovascular diseases were defined based on the 
questionnaire and medical laboratory examination. The self reported questions were 
used to define some of comorbidities, and the subjects were  asked similar questions, 
including coronary heart disease (“Has a doctor or other health professional ever told 
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you that you had a coronary heart disease?”), congestive heart failure (“Has a doctor or 
other health professional ever told you that you had congestive heart failure?”), stroke 
(“Has a doctor or other health professional ever told you that you had a stroke?”) and 
angina pectoris (“Has a doctor or other health professional ever told you that you had an 
angina pectoris?”), and heart attack ("Has a doctor or other health professional ever told 
you that you had Heart Attack?"). Chronic Kidney Disease (CKD) is defined by self 
report and estimation of glomerular filtration rate (GFR). All individuals with GFR <60 
mL/min/1.73 m2 are classified as CKD. GFR estimation was done according to 
Epidemiology Collaboration equation. Serum creatinine values were collected from the 
NHANES dataset. Persistent presence of more than 30 mg albumin per gram creatinine 
in the urine is diagnostic of chronic kidney disease. Microalbuminuria is a level of 30–
299 mg/L (Bowling, Sharma, Fox, O'Hare, & Muntner, 2013).  
 
 
III.IV Retinal Imaging Evaluation  
 Procedures for ophthalmological retinal imaging evaluation have been described 
previously (Klein, et al., 1999).  The retinal imaging evaluation was adapted from the 
Wisconsin Age-Related Maculopathy Grading Scheme (Klein et al., 1991). The 
presence of any drusen, soft drusen, retinal pigment epithelial (RPE) depigmentation 
and increased retinal pigment were assessed. GA was determined by absence of the 
RPE in which choroidal vessels are visible. The signs of CNV contain subretinal 
hemorrhage and fibrous scar, and retinal pigment epithelium detachment. Early AMD 
was determined by the presence of either soft drusen consistent with Grade 3 drusen or 
any drusen type with areas of depigmentation or hypopigmentation of the retinal 
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pigment epithelium without any visibility of choroidal vessels or with increased retinal 
pigment in the macular area. Late AMD was determined by the presence of signs of 
CNV or GA. RPE depigmentation was graded as present or absent. Increased retinal 
pigment which is the presence of granules or clumps of gray or black pigment in or 
beneath the retina was graded as present or absent. Retinal photograph was taken 
under a dilated eye.  Retinal image is the field centered horizontally and vertically.  
 
 
III.V Statistical Analysis 
 All analyses were conducted by using SAS 9.3 (SAS Institute, Cary, NC). 
Frequency distributions, percentages and means, and standard deviation were used to 
describe the difference of sociodemographic characteristics of the NHANES study 
population relating to AMD. The significance of the differences among categorical 
variables were determined by Chi square statistics, and Wilcoxon Rank Sum were used 
to test the difference among continuous variables based on the sample distribution and 
equality of variance. Univariate and multiple logistic regression models were used to 
assess the association between AMD and potential confounders including age, gender, 
race/ethnicity, alcohol consumption, education level, smoking status, and annual family 
income. Full sample 2 year interview and MEC exam weight were used to weight all 
survey samples. All analysis used weighted and stratified sample. 
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CHAPETER IV 
RESULTS 
IV.I Prevalence of AMD Stratified by Age in NHANES Population 2005 - 2008 
 The total number of participants who were aged 40 years or older were 4596 with 
a completion of examination of retinal image.  Among them, the number of people who 
had AMD were 441. The overall weighted  prevalence of AMD was 7%. Compared to 
the individuals whose age were 40-49 years old, the weighted prevalence of AMD were 
10% for those aged 70 years or older, 5% for those aged 60- 69 years, and 2%  for 
those 50-59 years, respectively (Table1). 
 
 
IV.II Descriptive Analysis of Study Population with or without of AMD 
 The characteristics of 2005-2008 NHANES population with or without AMD was 
summarized in Table 2. Briefly, average of the age among individuals with AMD was 68 
years old, and 87% of study population was whites, which were significantly higher than 
those among the individuals without AMD ( Age: 56, Whites: 76%, P value <0.05). The 
gender did not differ between two groups. The proportion of annual family incomes 
among the individuals with AMD was significantly difference from those among the 
participants without AMD (P value <0.05). The proportion of annual family incomes 
greater than $75K in individuals with AMD was 10%, which was significantly lower than 
Table 1. Weighted prevalence of AMD stratified by age: Adults 40 years or older, 2005 -2008 NHANES 
 
Outcome 
Participation's age  (Years ) (OR, 95 %CI ) 
40 - 49  50 - 59  60 - 69  70  or older 
 
AMD  
1.00  
(Reference)  
1.90 
(1.89-1.91) 
4.53 
( 4.512 - 4.534)  
9.85 
( 9.83 - 9.88 ) 
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those among the individuals without AMD (22%). Level of education did not differ 
between individuals without or with AMD. The proportion of current smokers with AMD 
(15%) was lower comparing to those without AMD (19%, P value <0.05) in this 
population. The proportion of AMD among the regular alcohol drinker (47%) was lower 
compared to those without AMD (60%, P-value<0.05). The level of HDL was 
significantly differ between AMD and non AMD participants (P<0.05); whereas, the 
levels of TCL, triglycerides and LDL were not statistically different (Table 2).  
Table 2. Characteristics of participants with or without AMD: Adults aged 40 years or 
older, AMD defined by retinal photography, NHANES 2005-2008  
 
Characteristics   
No AMD a  
(N= 4596)  
AMD a  
(N =441) 
 
P value c  
Demographic                                                                                                              
Age (year)
b
 55.6 (55.2-55.9) 68.0 (66.4-69.6)    <0.0001 
Gender                                                                                                                             0.8960 
   Male  47.4 (45.7-49.2) 47.0 (41.3-52.8)  
   Female 52.6  (50.8-54.3) 53.0 (47.2-58.7)  
Race/ Ethnicity                                                                                                       <0.0001 
   Non-Hispanic Whites 76.4 (75.3-77.6) 86.6 (83.6-90.0 )  
   Non-Hispanic Blacks 8.1 (7.2-9.0) 3.76 (2.4-5.1 )  
   Mexican American 8.1 (7.2-9.0) 5.5 (3.2-7.8)  
   The others 5.5 (5.1-5.9) 4.2 (2.9-5.5 )  
Socioeconomic 
Education                                                                                                                                   0.0736 
   High school graduate               44.0 (42.2-45.7) 49.6 (43.9-55.3 )  
   College or Associate 28.3 (26.8-29.9) 28.8 (23.5-34.1 )  
   College graduate or above 27.7 (26.1-29.3) 21.6 (16.6-26.6 )  
Family annual income                                                                                                  <0.0001 
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    <$25,000  26.0 (24.6-27.5) 36.4  (30.8-42.0)  
    $25,000-$4999  35.2 (34.4-38.0) 41.1(35.0-47.2)  
   $50,000-$74999 16.5 (15.0-18.0) 12.2 ( 7.3-17.0)  
   >$75,000 22.2  (20.6-23.9) 10.4 (6.3-14.5)  
Smoking status                                                                                                                          0.0203 
   None current smoker 81.3 (80.0-90.0) 85.0 (80.7-89.4)  
   Current smoker 18.7 (17.3-20.0) 15.0 (10.6-19.3)  
Alcohol consumption                                                                                                                 0.0079 
   None regular  drinker 39.6 (36.6-42.7) 53.1 (43.5-63.7)  
   Regular drinker 60.4 (57.3-63.4) 46.9 (37.3-56.5 )  
Medical examinational 
Body Mass Index (BMI)                                                                                                            0.0654 
   <18.5 2.0 (1.6-2.5) 1.1 (0.2-2.0 )  
   18.5 -24.99 26.0 (24.5-27.6) 29.9 (24.5-35.3)  
   25-29.99 35.1 (33.4-36.7) 38.3 (32.7-43.8 )  
   >30 36.9 (35.2-38.5) 30.7 (25.4-36.0)  
Total Cholesterol  (mg/dL )
                                                                                                                                                            
0.7235 
   <200  50.3 (48.5-52.0) 50.7 (45.0-56.5)  
   200-239 31.8 (30.2-33.5) 33.2 (27.6-38.8)  
   >240 17.9 (16.5-19.2) 16.1 (11.9 -20.3)  
Triglycerides (mg/dL)
 
      0.2465 
   <150 83.8 (82.5-85.1) 85.8 (82.1-90.0)  
   150-199 
   200-500 
7.9 (6.9-8.8) 6.2 (3.8-8.7)  
3.7 (3.1-4.4) 4.9 (2.6-7.3)  
   > 500 4.6 (3.9-5.3) 3.0 (1.1-4.9)  
LDL (mg/dL)
                                                                                                                                                     
                            0.8518 
   <129 82.6 (81.2 -83.9) 80.7 (75.7-85.7)  
   130-159 11.8 (10.7-12.9) 13.5 (9.0-17.9)  
   160-190 4.1 (3.4-4.8) 4.4 (1.9-7.0)  
   >190 1.6 (1.1-2.0) 1.4 (0.2-2.6)  
HDL (mg/dL)
 
      0.0288 
   <40 20.1 (18.7-21.5) 17.2 (12.9-21.5)  
   40-60 49.8 (48.1-51.6) 45.2 (39.5-50.9)  
   > 60 30.1 (28.5-31.8) 37.5 (31.9-43.2)  
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Values for categorical variables presented weighted proportion and 95% CI , and P-values were 
generated by Chi square test. Values for continues variables were weighted mean and 95% CI and P-
values were generated by F-test .
 a  
= % (95% CI); 
b
 =  mean (95% CI).  
c 
=  P value <0.05. LDL: Low 
density lipoprotein; HDL: High density lipoprotein; CI: Confidence interval. 
 
 
 We also compared these sociodemographic characteristics among the 
individuals with early or late AMD to those without AMD. These characteristics of early 
AMD results were similar  to the participants without AMD, however, the mean of age 
(78 years) among the individuals with late AMD were significantly older than those with 
early AMD (67 years), and higher proportion of whites in late AMD participants (94%, P-
value <0.05) were observed compared with early AMD (86%). Females with late AMD 
were more likely to have AMD (70%  versus 52% early AMD) (Table 3).  
 
Table 3. Characteristics of participants with early/late AMD: Adults aged 40 years or older, 
AMD defined by retinal photography,  NHANES 2005-2008  
 
Characteristics   
Early AMD a 
 (N=441)  
Late AMD a  
(N =51) 
 
P value c 
Demographic                                                                                                           
Age (year)
b
 66.6(64.9-68.3) 78.0 (76.2-80.0)     <0.0001 
Gender                                                                                                                                        0.0724 
   Male  49.4 (43.9-55.6) 30.1 (17.4-42.8)  
   Female 52.2 (46.2-58.2) 69.7 (57.2-82.6)  
Race/ Ethnicity                                                                                                                          <0.0001 
   Non-Hispanic Whites 86.0 (82.8-89.1) 94.4 (89.4-99.2)  
   Non-Hispanic Blacks 5.6 (3.1-8.0) 2.2 (0-5.5)  
   Mexican American 4.7 (3.2-6.2) 0.6 (0-1.8)  
   The others 4.0 (2.5-5.5) 0.5 (0-6.2)  
Socioeconomic 
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Education                                                                                                                                    0.1028 
   High school graduate               49.2 (43.0-55.5) 52.1 (37.8-66.5)  
   College or Associate 27.6 (22.2-33.1) 37.8 (21.0-48.6)  
   College graduate or above 22.4 (17.1-27.8) 13.1 (3.2-23.0)  
Family annual income                                                                                                               <0.0001 
   <$25,000  33.9 (29.5-41.1) 53.0 (37.5-68.5)  
   $25,000-$4999  41.1 (34.5-47.7) 40.8 (25.2-56.3)  
   $50,000-$74999 13.9 (8.5-19.4) 0  
    >$75,000 11.0 (6.4-15.6) 6.2 (0-13.4)  
Smoking status                                                                                                                          0.1596 
   None current smoker 85.0(80.3-90.0) 89.2 (80.3-98.0)  
   Current smoker 15.0 (10.2-19.7) 10.9 (2.0-19.7)  
Alcohol consumption                                                                                                                  0.0024 
   None regular  drinker 49.0 (38.3-59.8) 73.2 (55.6-90.9)  
   Regular drinker 51.0 (40.2-61.7) 26.8 (9.1-44.5)  
Medical examinational                                                                                                 
Body Mass Index (BMI)                                                                                                               0.0338 
   <18.5 0.9 (0-1.8) 2.4 (0-5.7)  
   18.5 -24.99 28.9 (23.0-34.7) 37.3 (23.2-51.5)  
   25-29.99 37.4 (31.4-43.3) 44.6 (30.3-58.8)  
   >30 32.8 (27.0-38.6) 15.7 (6.2-25.1)  
Total Cholesterol  (mg/dL )
                                                                                                                                   
        0.5664 
   <200  50.6 (44.4-56.9) 51.3 (37.0-65.6)  
   200-239 34.3 (8.2-40.4) 25.3 (13.1-37.4)  
   >240 15.1(10.6-19.5) 23.4(11.3-35.5)  
Triglycerides (mg/dL)
 
       0.5731 
   <150 86.2 (82.2-90.1) 83.5 (72.4-94.6)  
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   150-199 6.0 (3.4-8.5) 8.3 (0.1-16.5)  
   200-500 4..8 (2.3-7.3) 5.9 (0-13.2)  
   > 500 3.1 (1.0-5.1) 2.2 (0-6.6)  
LDL (mg/dL)
                                                                                                                                                     
      0.9134 
   <129 80.6 (75.1-86.0) 81.8 (70.6-92.9)  
   130-159 13.9 (9.0-18.8) 10.1 (0.8-19.3)  
   160-190 4.3 (1.6-7.1) 5.2 (0-11.0)  
   >190 1.2 (0-2.4) 2.3 (0-7.5)  
HDL (mg/dL)
 
      0.0411 
   <40 18.3 (13.5-23.0) 9.7 (1.3-18.1)  
   40-60 45.1 (38.9-51.3) 46.2 (32.0-60.5)  
   > 60 36.6 (30.5-42.7) 44.1 (30.0-58.4)  
See Table 1's footnote. P-values presented the comparisons of either early or late AMD to none-AMD 
 (iiTable 2).  
 
 
IV.III Prevalence of Vascular and Renal Comorbidities and AMD in the 2005-2008 
NHANE 
 The proportions of these comorbidities were estimated in the individuals with or 
without AMD by using the NHANES data combining 2 surveys. Among the individuals 
with AMD, 6% had AP, 10% had CHD, 7% had CHF, 10% had MI, 13% had stroke, and 
29% had CKD. The weighted prevalence were significantly higher than those among 
individuals without AMD (AP: 3%; CHD: 5%; CHF: 3%; MI: 5%; Stroke: 4%; CKD: 12%, 
P-value <0.05) (Table4).  
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Table 4. Weighted prevalence of vascular and renal comorbidities with or without AMD: 
Adults aged 40 years or older, AMD defined by retinal photography, 2005-2008 NHANES  
 
Medical  conditions 
No AMD  AMD   
P value Weighted %(95%CI) Weighted %(95%CI) 
Angina Pectoris  (AP) 3.2 (2.7-3.7) 6.1 (3.7-8.5) 0.0033 
Coronary heart disease  (CHD) 4.5 (3.8-5.1) 10.3 (7.0-13.6) <0.0001 
Congestive heart failure  (CHF) 3.0 (2.6-3.5) 7.3 (4.5-10.2 ) <0.0001 
Myocardial Infarction  (MI) 4.5( 3.9-5.2) 10.1 ( 7.0-13.2) <0.0001 
Stroke 3.5 (3.0-4.1 ) 12.5 ( 9.0-16.1) <0.0001 
Chronic Kidney Disease  (CKD) 10.8 (9.8-11.8 ) 28.8(23.8-33.8) <0.0001 
Values present weighted proportion (%) and 95% Confidence interval (CI). Rao-Scott Chi-Square 
statistics were used for the comparison between no AMD and AMD. 
 
 When we examined the weighted prevalence of these comorbidities among the 
individuals with early or late AMD, results were similar; however, the proportions of 
stroke (26%) and CKD (49%) in the participants with late AMD were significantly higher 
than those without AMD (P value<0.05) (Table 5 ).  
Table 5.Weighted prevalence of the cormorbidites with early or late AMD or without AMD: 
Adults aged 40 years or older, AMD defined by retinal photography, 2005-2008 NHANES 
 
Medical  
conditions 
No AMD Early AMD Late AMD  
P value Weighted % 
(95%CI) 
Weighted 
%(95%CI) 
Weighted 
%(95%CI) 
AP 3.2 (2.7-3.7) 6.6 (3.9-9.3) 2.1 (0-5.3) 0.009 
CHD 4.5 (3.8-5.1) 10.2 (6.6-13.8) 10.6 (2.3-19.1) <0.0001 
CHF 3.3 (2.6-3.5) 6.5(3.5-9.4) 13.4 (3.5-23.3) <0.0001 
MI 4.5( 3.9-5.2) 10.2 (6.8-13.6) 9.3 (2.0-16.6) <0.0001 
Stroke 3.5 (3.0-4.1 ) 10.7(7.2-14.3) 26.4(13.2-39.5) <0.0001 
CKD 10.8 (9.8-11.8 ) 26.0 (20.7-31.2) 49.4 (35.1-63.8) <0.0001 
Values present weighted proportion (%) and 95% Confidence interval (CI).  Rao-Scott Chi-Square 
statistics were used for the comparison between no AMD and  early/late AMD. 
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IV.IV Association Between Each Single Comorbidity and AMD in the 2005-2008 NHANE 
 To address the association of each single vascular and renal comorbidity with 
AMD, we, first, conducted univariate logistic regression analysis. ORs were estimated. 
The crude ORs for all AMD among the participants with these conditions (AP, CHD, MI, 
CHF, HD and stroke) were 2.0 (95% CI:1.2-3.1), 2.5 (95% CI: 1.7-3.6), 2.4 (95% CI: 
1.6-3.5), 2.5 (95% CI: 1.6-4.0), 2.6 (95%CI: 2.0-3.4) and 3.9 (2.7-4.4), respectively. In 
addition, the crude OR for AMD was 3.4 (95%CI: 2.6-4.4) among the individuals with 
CKD. After controlling for gender, age, race/ethnicity, current smoke status, alcohol 
consumption, and annual family incomes, and level of serum HDL, the adjusted ORs for 
AMD were  similar to the crude ORs among the individuals with CHD (2.3, 95% CI: 1.4-
3.7), MI (2.2, 95% CI: 1.3-3.5), CHF (2.0, 95% CI: 1.1-3.8), HD (2.0, 95% CI: 1.4- 2.9), 
and stroke (3.0, 95%CI: 1.8-4.9) and CKD ( 2.4, 95%CI: 1.7-3.4), respectively; however, 
the adjusted OR for the AMD among the individuals with AP was no longer significant 
(1.5, 95% CI: 0.8-2.7).  We also examined the crude and adjusted ORs for early AMD 
using the same logistic regression models, similar results were observed (Table 6). 
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Table 6. Association between a single comorbidity and AMD, respectively : Adults age 40 
years or older, AMD defined by retinal photography, 2005-2008 NHANES  
 
 Medical conditions 
AMD Early AMD 
Crude OR 
( 95%CI ) 
Adjusted OR  
( 95%CI ) 
Crude OR 
 ( 95%CI ) 
Adjusted OR 
 ( 95%CI ) 
AP 1.96 (1.24-3.10) 1.50 (0.83-2,71) 2.05 (1.29-3.27) 1.59 (0.88-2.87) 
CHD 2.46 (1.67-3.64) 2.27 (1.35-3.67) 2.44 (1.63-3.66) 2.17 (1.30-3.62) 
MI 2.38 (1.64-3.45) 2.20 (1.34-3.51) 2.34 (1.59-3.44) 2.12 (1.29-3.49) 
CHF 2.51 (1.60-3.95) 1.98 (1.05-3.75) 2.44 (1.52-3.92) 2.09 (1.10-3.97) 
HD 2.59 (1.95-3.43) 2.01 (1.38-2.93) 2.57 (1.91-3.45) 2.04 (1.39-3.00) 
Stroke 3.91 (2.72-4.36) 2.99(1.82-4.92) 2.37 (2.55-5.44) 2.12 (0.57-7.80) 
CKD 3.35 (2.57-4.36) 2.44 (1.73-3.43) 2.99 (2.26-3.96) 2.32 (1.63-3.31) 
Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family incomes, 
and level of HDL Abbreviations: HD: either AP or CHD or CHF or MI. OR, odds ratio 
 
IV.V Association of Combination of  Comorbidities and AMD 
 To investigate whether there is a strong association of these comorbidities with 
AMD, we conducted the logistic regression analysis with. Without any condition was 
defines as a reference group. We found that crude ORs for AMD were 2.8 (95% CI: 2.9-
3.9) among the individuals with any one condition, 3.9 (95% CI: 2.7-5.7) among the 
participants with any two conditions or more. The association was statistically significant 
(P-value <0.05). After controlling for age, gender, race/ethnicity, smoking status, alcohol 
consumption and annual family incomes, and the level of HDL, the association 
remained a significant level (P-value <0.05). We also examined whether the c 
association was presented in early AMD (P<0.05). The results were similar (Table 7).   
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Table 7.  Association of combination of comorbidity with AMD: Adults aged 40 years or older, 
AMD defined by retinal photography, 2005-2008 NHANES  
 
Medical conditions 
AMD Early AMD 
Crude OR 
(95%CI) 
Adjusted OR 
(95%CI) 
Crude  
OR (95%CI) 
Adjusted OR  
(95%CI) 
None (Reference) 1.00 1.00 1.00 1.00 
Any one   2.78 (2.00-3.87) 2.60 (1.71-3.92) 2.67 (1.89-3.77) 2.56 (1.68-3.92) 
Any two or more  3.93 (2.69-5.73) 2.33 (2.73-3.99) 3.60  (2.42-5.36) 2.31 (1.33-4.01) 
Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family 
incomes and level of HDL. Abbreviations: one condition, either HD or CKD or stroke; two 
conditions, any combination of two among HD, CKD and stroke; OR, odds ratio.  
 
IV.VI Association of Specific Combination of Comorbidities with AMD in the 2005-2008 
NHANES 
 To estimate whether there is an association among a specific combination of 
these comorbidities, we analyzed the ORs for AMD among three specific combinations 
of comorbidities (HD/Stroke, HD/CKD and Stroke/CKD) using the same logistic 
regression model designed above with same controlling factor. We found that the crude 
ORs for AMD were 4.0 (95%CI: 3.3-7.0), 3.9 (2.6-5.8) and 7.4 (4.5-12.2) among the 
individuals with HD/Stroke, HD/CKD and Stroke/CKD, respectively. With controlling for 
the adjusted factors, the associations remained same. In addition, we estimated these 
associations for early AMD, the results were similar (Table 8)   
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Table 8. Association of specific combination of co-morbidity with AMD: Adults aged 40 years or 
older, AMD defined by retinal photography, 2005 - 2008 NHANES 
 
Medical conditions 
AMD Early AMD 
Crude 
 OR ( 95%CI ) 
Adjusted  
OR ( 95%CI ) 
Crude 
 OR ( 95%CI ) 
Adjusted 
 OR ( 95%CI ) 
HD/Stroke 404 (2.34-6.96) 2.25 (1.00-5.07) 4.16 (2.39-5.26) 2.37 (1.06-5.33) 
HD/ CKD 3.88 (2.58-5.80) 2.43 (1.36-4.34) 3.40 (2.19-5.26) 2.39 (1.31-4.33) 
Stroke/ CKD 7.43 (4.51-12.27) 5.50 (2.74-11.02) 6.92 (4.12-11.61) 5.87(2.94-11.74) 
Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family incomes 
and level of HDL 
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
The association of vascular or renal comorbidities with AMD has been reported 
inconsistently with some studies showing a significant association, and others not 
showing the association. To our knowledge, this study is first to investigate a 
relationship of combination of these comorbidities with AMD by utilizing the large 
nationally representative sample of US. We found that the prevalence of six vascular 
and renal conditions (AP, CHD, CHF, MI, Stroke and CKD) among individuals with AMD 
was significantly higher than those without AMD. Each of six comorbidities was 
significantly associated with AMD by the analysis of univariate logistic regression, 
respectively; whereas, the association was no longer existing in individuals with AP, 
other conditions remained the association, after controlling for age, gender, 
race/ethnicity, family annual income, smoking status, alcohol consumption and the level 
of HDL. Comparing to individuals without three conditions (HD, Stroke and CKD), the 
crude ORs of AMD increased 2-fold with the presence of any one and 4-fold with any 
two conditions and more, respectively. The adjusted ORs were attenuated, but 
remained significantly difference. Furthermore, the individuals with both stroke and CKD 
were strongly associated with AMD. Correspondently, we found that the prevalence of 
both stroke and CKD among individuals with AMD were approximately 3 times higher 
than those among individuals without AMD.  Similar results were observed in early 
AMD. The findings may provide insight for appropriate preventive measurement for 
health care management.  
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Our results indicate that there is an association of vascular and renal 
comorbidities with AMD. Several possible reasons that would explain it. AMD shares 
common risk factors with these comorbidities, for example, smoking (Erke et al., 2014; 
Snow & Seddon, 1999). The pathological regions for these three comorbidities are all 
involved with the abnormalities of blood vessels. The abnormalities are commonly 
correlated to atherosclerosis. AMD shares pathological similarities with atherosclerosis 
(Machalinska, Kawa, Marlicz, & Machalinski, 2012). According to the association seen 
in this study, a potential hypothesis is that atherosclerosis occurred at the choroidial 
circulation may contribute to the development of AMD. Dyslipidemia is well-known risk 
factor of vascular diseases. Reducing the level of HDL could lead to preventive 
outcomes (Schaefer, 2012). The high level of HDL seen in the AMD participants in this 
study reveals that the dyslipidemia may be a common risk factor of AMD and vascular 
and renal diseases. It shed the light that reducing the level of HDL would lead to the 
potential prevention of development of AMD. The most recent study revealed an 
association of cholesteryl ester transfer protein (CETP) gene with neovascular AMD (Liu 
et al., 2014), Out results might indicate a potential to investigate the gene-related 
relationship not only in neovascuar AMD, but in all type of AMD.  
The most interesting finding of this study is a strong relationship of combination 
of stroke and CKD with AMD. Microvascular alteration in the retinal circulation and the 
retinal pigment epithelium play important roles in the pathology of AMD. Kidney damage 
generally is considered from burden of microvascular and systematic epithelium. 
Furthermore, genetic predisposition of kidney disease and AMD share similar 
involvement of alternative complement pathway (Ansari et al., 2013; Ma et al., 2014; 
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Zhan et al., 2013). Both common shared pathological pathways and genetic 
predisposition similarities, therefore, may explain the strong association of the 
combination of the comorbidities with AMD, particularly in the combination of stroke and 
CKD. .    
There are important implications of our results. The estimates of prevalence in 
this study provide the probabilities of presence of these comorbidities, the presence of 
higher probabilities among individuals with AMD compared with those without AMD 
should trigger a further longitudinal study for the potential coexistence of these 
comorbidities. If there is temporal relationship between comorbidities and AMD, these 
vascular and renal comorbidities will need to be recognized as a potential risk factor of 
AMD. These comorbidities should be managed and measured in the AMD care 
management.  
Management of AMD should take into account these vascular and renal diseases 
because coexisting these comorbidities and AMD will lead the worse health outcome. 
These comorbidities could be potential risk factor indicators for eye care management in 
order to early detect AMD. For example, increased frequency of regular eye 
examination among people who have these comorbidities would be ideal. Furthermore, 
the preventive strategies and managements for vascular and renal disease could be 
applied to AMD-risk population. For instance, change in the life style behavior, such as 
physical activity.  
Strengths and limitation of this study deserve to be discussed. This study was 
using nationally representatively sample of US with a continuous 2 years surveys, 
therefore, the results more likely lead to generalizability of US population. Also, 
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standardized retinal image examination was conducted to our study, and individuals 
with a completion of the retinal image examination were include in the study population 
to determine the presence of drusen and pigment alteration, this minimized the 
misclassification of diagnosis of AMD,  while the cross-sectional study design can not 
address a potential temporal relationship between these comorbidities and AMD. 
Further research for longitudinal studies would be desirable to investigate the plausible 
relationship. In order to minimize the misclassification from self-reported diagnosis for 
the comorbidities related to heart diseases, the variable of heart disease was defined by 
mutual exclusive of each heart condition. Thus, it is unlikely that misclassification of 
diagnosis would explain the strong association observed in this study.  
 
In conclusion, these findings from a nationally representative US population 
highlight the remarkable association between vascular and renal comorbidities of AMD. 
Give the worse outcome of AMD associated with these comorbidities, these 
comorbidities should be take account into the eye care management for not only AMD 
patient, but also AMD-risk population. The preventive strategies for vascular and renal 
conditions should be preferred to be applied to AMD care management.  
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ABBREVIATIONS 
AP: Angina Pectoris  
AMD: Age-related macular degeneration 
CHD: Coronary heart disease 
CHF: Congestive heart failure 
CI: Confidence Interval  
HD: Heart disease 
MI: Myocardial Infarction 
CKD: Chronic kidney disease 
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